1. School of Pharmaceutical Science, Wenzhou Medical University,Zhejiang,Wenzhou,China,325035
2. College of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju 61186, Republic of Korea
3. Department of Dermatology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine,Zhejiang,Wenzhou,China,325000
4. Zhejiang Lab for Regenerative Medicine, Oujiang Laboratory,Zhejiang,Wenzhou,China,325035
Published:2024,
Published Online:1 January 2024,
扫 描 看 全 文
Yanran Bi, Ruiling Zheng, Jiahao Hu, et al. A novel FGFR1 inhibitor CYY292 suppresses tumor progression, invasion, and metastasis of glioblastoma by inhibiting the Akt/GSK3β/snail signaling axis. [J]. Genes & Diseases 1(1):479-494(2024)
Yanran Bi, Ruiling Zheng, Jiahao Hu, et al. A novel FGFR1 inhibitor CYY292 suppresses tumor progression, invasion, and metastasis of glioblastoma by inhibiting the Akt/GSK3β/snail signaling axis. [J]. Genes & Diseases 1(1):479-494(2024) DOI: 10.1016/j.gendis.2023.02.035.
Glioblastoma (GBM) is a malignant brain tumor that grows quickly
spreads widely
and is resistant to treatment. Fibroblast growth factor receptor (FGFR)1 is a receptor tyrosine kinase that regulates cellular processes
including proliferation
survival
migration
and differentiation. FGFR1 was predominantly expressed in GBM tissues
and FGFR1 expression was negatively correlated with overall survival. We rationally designed a novel small molecule CYY292
which exhibited a strong affinity for the FGFR1 protein in GBM cell lines
in vitro
. CYY292 also exerted an effect on the conserved Ser777 residue of
FGFR1
. CYY292 dose-dependently inhibited cell proliferation
epithelial–mesenchymal transition
stemness
invasion
and migration
in vitro
by specifically targeting the FGFR1/AKT/Snail pathways in GBM cells
and this effect was prevented by pharmacological inhibitors and critical gene knockdown.
In vivo
experiments revealed that CYY292 inhibited U87MG tumor growth more effectively than AZD4547. CYY292 also efficiently reduced GBM cell proliferation and increased survival in orthotopic GBM models. This study further elucidates the function of FGFR1 in the GBM and reveals the effect of CYY292
which targets FGFR1
on downstream signaling pathways directly reducing GBM cell growth
invasion
and metastasis and thus impairing the recruitment
activation
and function of immune cells.
Blood-brain barrierEMTFGFR1FGFR1 inhibitorGlioblastoma
1 M.E. DavisGlioblastoma: overview of disease and treatment Clin J Oncol Nurs, 20 (5 Suppl) (2016), pp. S2-S8
2 A. Ou, W.K.A. Alfred Yung, N. MajdMolecular mechanisms of treatment resistance in glioblastoma Int J Mol Sci, 22 (1) (2020), p. 351
3 T.A. Juratli, N. Qin, D.P. Cahill, et al.Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas Pharmacol Ther, 182 (2018), pp. 70-79
4 K. Aldape, G. Zadeh, S. Mansouri, et al.Glioblastoma: pathology, molecular mechanisms and markers Acta Neuropathol, 129 (6) (2015), pp. 829-848
5 C. Festuccia, A.L. Biordi, V. Tombolini, et al.Targeted molecular therapy in glioblastoma J Oncol, 2020 (2020), Article 5104876
6 I.C. Iser, M.B. Pereira, G. Lenz, et al.The epithelial-to-mesenchymal transition-like process in glioblastoma: an updated systematic review and in silico investigation Med Res Rev, 37 (2) (2017), pp. 271-313
7 V. MittalEpithelial mesenchymal transition in tumor metastasis Annu Rev Pathol, 13 (2018), pp. 395-412
8 H.M. Li, Y.R. Bi, Y. Li, et al.A potent CBP/p300-Snail interaction inhibitor suppresses tumor growth and metastasis in wild-type p53-expressing cancer Sci Adv, 6 (17) (2020), Article eaaw8500
9 C. Tao, K. Huang, J. Shi, et al.Genomics and prognosis analysis of epithelial-mesenchymal transition in glioma Front Oncol, 10 (2020), p. 183
10 Y. IwadateEpithelial-mesenchymal transition in glioblastoma progression Oncol Lett, 11 (3) (2016), pp. 1615-1620
11 L.H. Zhang, Y.H. Yin, H.Z. Chen, et al.TRIM24 promotes stemness and invasiveness of glioblastoma cells via activating Sox 2 expression Neuro Oncol, 22 (12) (2020), pp. 1797-1808
12 A. Jimenez-Pascual, J.S. Hale, A. Kordowski, et al.ADAMDEC1 maintains a growth factor signaling loop in cancer stem cells Cancer Discov, 9 (11) (2019), pp. 1574-1589
13 G. Marseglia, A. Lodola, M. Mor, et al.Fibroblast growth factor receptor inhibitors: patent review (2015-2019) Expert Opin Ther Pat, 29 (12) (2019), pp. 965-977
14 N. Turner, R. GroseFibroblast growth factor signalling: from development to cancer Nat Rev Cancer, 10 (2) (2010), pp. 116-129
15 M. Katoh, H. NakagamaFGF receptors: cancer biology and therapeutics Med Res Rev, 34 (2) (2014), pp. 280-300
16 S. Dai, Z. Zhou, Z. Chen, et al.Fibroblast growth factor receptors (FGFRs): structures and small molecule inhibitors Cells, 8 (6) (2019), p. E614
17 A. Jimenez-Pascual, F.A. SiebzehnrublFibroblast growth factor receptor functions in glioblastoma Cells, 8 (7) (2019), p. 715
18 M. Touat, E. Ileana, S. Postel-Vinay, et al.Targeting FGFR signaling in cancer Clin Cancer Res, 21 (12) (2015), pp. 2684-2694
19 K. Koole, D. Brunen, P.M. van Kempen, et al.FGFR1 is a potential prognostic biomarker and therapeutic target in head and neck squamous cell carcinoma Clin Cancer Res, 22 (15) (2016), pp. 3884-3893
20 V. Gouazé-Andersson, M.J. Ghérardi, A. Lemarié, et al.FGFR1/FOXM1 pathway: a key regulator of glioblastoma stem cells radioresistance and a prognosis biomarker Oncotarget, 9 (60) (2018), pp. 31637-31649
21 D.J. Pennisi, T. MikawaFGFR-1 is required by epicardium-derived cells for myocardial invasion and correct coronary vascular lineage differentiation Dev Biol, 328 (1) (2009), pp. 148-159
22 M. Zakrzewska, E.M. Haugsten, B. Nadratowska-Wesolowska, et al.ERK-mediated phosphorylation of fibroblast growth factor receptor 1 on Ser777 inhibits signaling Sci Signal, 6 (262) (2013), p. ra11
23 J.C. Obenauer, L.C. Cantley, M.B. YaffeScansite 2.0:Proteome-wide prediction of cell signaling interactions using short sequence motifs Nucleic Acids Res, 31 (13) (2003), pp. 3635-3641
24 N. Hallinan, S. Finn, S. Cuffe, et al.Targeting the fibroblast growth factor receptor family in cancer Cancer Treat Rev, 46 (2016), pp. 51-62
25 A. Weaver, J.B. BossaerFibroblast growth factor receptor (FGFR) inhibitors: a review of a novel therapeutic class J Oncol Pharm Pract, 27 (3) (2021), pp. 702-710
26 V.S. Goodfellow, C.J. Loweth, S.B. Ravula, et al.Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3 J Med Chem, 56 (20) (2013), pp. 8032-8048
27 R. Jafari, H. Almqvist, H. Axelsson, et al.The cellular thermal shift assay for evaluating drug target interactions in cells Nat Protoc, 9 (9) (2014), pp. 2100-2122
28 L. Di, L.J. Liu, Y.M. Yan, et al.Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer J Exp Clin Cancer Res, 38 (2019), p. 134
29 I.S. Babina, N.C. TurnerAdvances and challenges in targeting FGFR signalling in cancer Nat Rev Cancer, 17 (5) (2017), pp. 318-332
30 A. Akinleye, P. Avvaru, M. Furqan, et al.Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics J Hematol Oncol, 6 (2013), p. 88
31 Q. Meng, S. Shi, C. Liang, et al.Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling Oncogene, 37 (44) (2018), pp. 5843-5857
32 B.P. Zhou, J. Deng, W. Xia, et al.Dual regulation of Snail by GSK-3 beta-mediated phosphorylation in control of epithelial-mesenchymal transition Nat Cell Biol, 6 (10) (2004), pp. 931-940
33 S. Bao, Q. Wu, R.E. McLendon, et al.Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Nature, 444 (7120) (2006), pp. 756-760
34 C. Wang, L. Zeng, T. Zhang, et al.Tenuigenin prevents IL-1β-induced inflammation in human osteoarthritis chondrocytes by suppressing PI3K/AKT/NF-κB signaling pathway Inflammation, 39 (2) (2016), pp. 807-812
35 S. He, Y. Fu, B. Yan, et al.Curcumol alleviates the inflammation of nucleus pulposus cells via the PI3K/Akt/NF-κB signaling pathway and delays intervertebral disk degeneration World Neurosurg, 155 (2021), pp. e402-e411
36 B. Hoesel, J.A. SchmidThe complexity of NF-κB signaling in inflammation and cancer Mol Cancer, 12 (2013), p. 86
37 M. Presta, P. Chiodelli, A. Giacomini, et al.Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach Pharmacol Ther, 179 (2017), pp. 171-187
38 R. Grose, C. DicksonFibroblast growth factor signaling in tumorigenesis Cytokine Growth Factor Rev, 16 (2) (2005), pp. 179-186
39 A. Giacomini, P. Chiodelli, S. Matarazzo, et al.Blocking the FGF/FGFR system as a “two-compartment” antiangiogenic/antitumor approach in cancer therapy Pharmacol Res, 107 (2016), pp. 172-185
40 R. Peng, Y. Chen, L. Wei, et al.Resistance to FGFR1-targeted therapy leads to autophagy via TAK1/AMPK activation in gastric cancer Gastric Cancer, 23 (6) (2020), pp. 988-1002
41 M. Mohammadi, I. Dikic, A. Sorokin, et al.Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction Mol Cell Biol, 16 (3) (1996), pp. 977-989
42 V. Sørensen, Y. Zhen, M. Zakrzewska, et al.Phosphorylation of fibroblast growth factor (FGF) receptor 1 at Ser777 by p38 mitogen-activated protein kinase regulates translocation of exogenous FGF1 to the cytosol and nucleus Mol Cell Biol, 28 (12) (2008), pp. 4129-4141
0
Views
0
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621
